Core Viewpoint - WuXi Biologics (02269.HK) reported a 16.1% year-on-year increase in revenue for the six months ending June 30, 2025, reaching RMB 9,953.2 million [1] Financial Performance - Gross profit increased by 27.0% year-on-year to RMB 4,252.9 million, with a gross margin improvement of approximately 3.6% [1] - Net profit attributable to the company owners rose by 54.8% to RMB 2,756.6 million, while net profit increased by 56.0% to RMB 2,339.3 million [1] Order Backlog - The total amount of uncompleted orders as of June 30, 2025, increased to USD 20.3 billion, which includes uncompleted service orders of USD 11.4 billion and uncompleted potential milestone payment orders of USD 9.0 billion [1] - The total amount of uncompleted orders over the next three years as of June 30, 2025, increased to USD 4.2 billion [1]